Fortress Biotech, Inc. (FBIO) 股票分析

公司概述

Fortress Biotech, Inc. operates as a biopharmaceutical entity dedicated to the development and commercialization of specialized biopharmaceutical products, with a specific focus on dermatology solutions such as Emrosi and Qbrexza. The company functions within the broader healthcare sector, specifically the biotechnology industry, positioning itself to address therapeutic needs for skin conditions including rosacea. In terms of operational scale, Fortress Biotech, Inc. maintains a total market capitalization of $77.29M and reports annual revenue of $63.26M, while its employee count is listed as N/A in available data. These valuation and revenue figures indicate that the company occupies a niche position within the biotechnology landscape, characterized by a relatively small market capitalization that reflects its early-to-mid stage commercialization efforts rather than established mass-market dominance.

财务健康

The company generated revenue of $63.26M over the trailing twelve months, yet recorded a net income of $-1,882,000 and an EBITDA of $-65,560,000, revealing a significant structural gap where operating expenses substantially exceed gross profits. This disparity highlights a cost structure typical of biotechnology firms in the growth phase, where research, development, and commercialization costs are high before products achieve widespread profitability. Fortress Biotech, Inc. reported a free cash flow of $-47,286,376, which signifies a consumption of cash reserves to fund ongoing operations and product development, thereby limiting immediate financial flexibility for external expansion or acquisitions. The company's profitability metrics further illustrate this challenge, with a gross margin of 48.1%, an operating margin of -29.8%, and a profit margin of 10.8%, indicating that while the core products are priced to cover direct costs, overheads and R&D expenses are eroding overall operational efficiency. Liquidity analysis shows the company holds $79.38M in cash against $67.22M in debt, resulting in a debt-to-equity ratio of 108.09, which suggests a highly leveraged balance sheet where equity capital is relatively small compared to total liabilities. Despite the high leverage, the current ratio stands at 2.49, indicating that the company possesses sufficient short-term liquid assets to cover its current liabilities more than twice over. Return on equity is reported at -108.7% and return on assets at -26.6%, metrics that reveal that management has yet to generate positive returns on shareholder or asset investments due to cumulative net losses.

估值评估

Valuation metrics present a complex picture due to the company's lack of consistent profitability, with a trailing P/E ratio of N/A and a forward P/E of -1.36. The negative forward P/E implies that the market is pricing in a return to profitability or expects earnings to be negative in the near term, making traditional earnings-based valuation methods inapplicable. The price-to-book ratio is 1.33, suggesting that the market values the company at approximately 33% above its book value, which may reflect intangible assets or future growth potential rather than current earnings power. Alternative valuation measures such as a price-to-sales ratio of 1.22 and an EV/EBITDA of -1.18 further underscore that investors are valuing the firm based on revenue generation and asset base rather than cash earnings. In terms of trading range, the 52-week high is $4.53 and the 52-week low is $1.33, placing the current trading environment within a volatile band where the stock has experienced significant price compression relative to its peak performance. The beta of 1.45 indicates that the stock's price volatility is significantly higher than the broader market, moving 45% more than the market average in response to systemic risk factors.

Growth & Income

Revenue growth for the trailing twelve months stands at 6.3%, while earnings growth is listed as N/A due to the company reporting a net loss. The absence of positive earnings growth relative to revenue growth implies that the company is prioritizing market share expansion and product rollout over immediate profitability, a common strategy in the biotechnology sector. As a non-dividend payer with a dividend yield of N/A and a payout ratio of 0.0%, the company does not distribute income to shareholders, effectively reinvesting all available capital back into research, development, and commercialization activities to fuel future growth. This growth-focused strategy, combined with the lack of current income generation, defines a high-risk, high-reward profile where shareholder returns are contingent upon the successful commercialization of pipeline assets rather than dividend income or current earnings expansion.